Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccine

31 Jan 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39892108
DOI: 10.1016/j.vaccine.2025.126787

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccinePMID 39892108Read ↗

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSemantic proximity Read ↗

First COVID-19 DNA vaccine approved, others in hot pursuitSemantic proximity Read ↗

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancerSemantic proximity Read ↗

Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development ArenaSemantic proximity Read ↗

Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector systemSemantic proximity Read ↗

An Overview of Vaccine Development for COVID-19Semantic proximity Read ↗

Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigensSemantic proximity Read ↗

A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 VaccineSemantic proximity Read ↗

Vaccines: past, present and futureSemantic proximity Read ↗

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical developmentSemantic proximity Read ↗

A Brief Review on Dna Vaccines in the Era of COVID-19Semantic proximity Read ↗

Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.